Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price target of $41.00. The company’s shares closed last ...

WALTHAM, Mass., February 06, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...

Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts expect that Viridian Therapeutics will post -4.03 earnings per share for ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that ...

Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...

WALTHAM, Mass., February 06, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for ...

Check Out Our Latest Research Report on VRDN Viridian Therapeutics Trading Up 1.1 % NASDAQ VRDN opened at $19.43 on Tuesday. The company’s 50-day moving average price is $19.42 and its 200-day ...

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

VRDN Viridian Therapeutics Inc Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Veligrotug, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...